ArticleJournal of translational medicine2025
Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEGFR exon 20 insertion mutations (ex20ins) represent the third most common epidermal growth factor receptor (EGFR) mutation subtype in non-small cell lung cancer (NSCLC). Conventional EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy demonstrate suboptimal efficacy in patients harboring EGFR ex20ins mutations. Furmonertinib, a highly selective EGFR-TKI with enhanced blood-brain barrier penetration, presents a potential therapeutic breakthrough. This study aims to evaluate the efficacy of double-dose furmonertinib (160 mg) in advanced EGFR ex20ins-mutant NSCLC patients and explore associations between predictive biomarkers and clinical outcomes.
methodsA retrospective analysis was conducted on 98 patients with locally advanced or metastatic EGFR ex20ins-mutant NSCLC. The observation group received double-dose furmonertinib (160 mg daily), while the control group received standard platinum-based doublet chemotherapy.
resultsThe observation group demonstrated significantly superior ORR (47.4 vs. 23.3%) and median PFS (8.7 vs 5.4 months) compared to the control group (P < 0.05).Within the observation group, pretreated patients exhibited reduced efficacy versus treatment-naïve patients (ORR 30 vs 66.7%; median PFS: 6.1 vs. 10.2 months; P < 0.05).The observation group reported lower overall adverse event (AE) incidence (60.5 vs. 71.7%) and reduced grade ≥ 3 AEs (21.1 vs. 28.3%) compared to the control group. Multivariate logistic regression identified peripheral blood T-lymphocyte subsets (CD4
conclusionsDouble-dose furmonertinib demonstrates significant efficacy and favorable tolerability in advanced EGFR ex20ins-mutant NSCLC, particularly in treatment-naïve patients. Pretreatment peripheral T-lymphocyte profiles and systemic inflammatory indices may serve as predictive biomarkers for therapeutic response and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.